Hemas Group revenue up by 21.9-pct over last year
Hemas Holdings PLC (HHL) recorded a Group revenue of Rs.57.7 billion, an increase of 20.5 percent over last year.
The underlying cumulative operating profit of Rs.4.9 billion, excluding all disposed entities, reported an increase of 4.3 percent over last year in spite of profitability pressure experienced across most parts of the business due to input cost inflation and challenges around foreign exchange liquidity. Underlying Group earnings excluding dividend tax stood at Rs. 3.3 billion, an increase of 7.2 per cent over last year.
During the quarter, Group revenue grew by 21.9 per cent over last year. The Group underlying operating profit and earnings of Rs.2.3 billion and Rs. 1.3 billion saw a year-on-year increase of 5.7 per cent and 2.4 per cent respectively. The Group’s Healthcare businesses, in particular, contributed to the improved performance.
The Group divested its interest in Spectra Logistics for a total consideration of Rs.1.3
billion in October 2021 and the gain realised in the sale amounted to Rs.295.3 million.
Consumer Brands
The pandemic coupled
with the macroeconomic headwinds continued to influence consumer behaviour,
sales mix and market channel dynamics. As we experienced lower infection rates,
the quarter under review was a near ‘normal’ quarter with minimal disruptions
to trade and operations. With the rising inflationary pressure, basket value
was skewed towards food and essentials, impacting shopper patterns for non-essential
items. The quarter continued to witness escalation in commodity prices by over 50
per cent against last year. Global supply chain disruptions coupled with import
restrictions in Sri Lanka underpinned by forex liquidity challenges exerted
pressure on profitability margins .
Operating conditions
in Bangladesh improved during the first two months into the quarter. However,
daily COVID infection rates were rising towards the latter part of the quarter.
During the quarter,
all schools were reopened, and the three-month prolonged trade union strike was
called off by the teachers and principals. Further, tuition classes were
allowed to operate with a 50 per cent capacity for O/L and A/L classes. As a
result, the quarter witnessed an increased demand.
The Consumer Brands
sector recorded a cumulative revenue of Rs.22.5 billion, a growth of 17.0 per
cent over last year. However, sector cumulative earnings of Rs.1.6 billion
witnessed a year-on-year decline of 14.8 per cent due to profitability pressure
as stated above.
During the quarter, the Consumer Brands sector registered
a revenue of Rs.9.7 billion, an increase of 22.2 per cent compared with the
corresponding quarter in FY 2021. Home and Personal care (HPC) segment continued
the growth momentum witnessed last year, whilst improved performance in Atlas contributed
positively towards the profitability. However, rising raw material prices led
to a decline in overall sector earnings by 18.2 per cent.
Home and Personal Care
HPC Sri Lanka delivered a steady volume-led
growth across both modern and general trade channels compared to last year. Similarly,
the recent launches and relaunches have been gaining good traction. Cumulative
revenue from new launches stood at 16.1 per cent over 13.5 per cent recorded
last year.
Sector profitability continues to
be impacted due to steep increases in raw material cost along with cost impact
due to foreign exchange liquidity pressures. In an ongoing effort to reduce the
burden to consumer from the inflationary impact, we have adopted multiple strategies
whilst continuing to prudently manage cost to recover margins.
HPC Bangladesh witnessed double digit cumulative revenue and
profitability growth due to improved market conditions in the first two months.
The business also experienced a similar trend in volume growth in comparison to
the last quarter whilst new launches continue to gain momentum in the market. Revenue
contribution from new launches stood at 16.9 per cent against a 5.7 per cent
reported last year.
Learning Segment
Atlas Axillia continued
to gain market share across all key categories including books, school and
colour products over last year with double digit volume growth through premiumization
by way of design and technology. Market share within the premium books category
was doubled with the relaunch of the Innovate
Brand.
Healthcare
Market demand for healthcare
services and medicines experienced a sudden surge with the COVID cases escalating. More outpatient visits
were registered as restrictions on mobility eased across the island. Medical
tourism witnessed improved performance with borders opening up and more
patients opting for elective surgeries. Further, acceleration of digital
adoption across the healthcare sector saw an increase in demand for digital
healthcare platforms.
The Sector reported a
cumulative revenue of Rs.33.7 billion, a growth of 23.7 per cent over last year
whilst sector profit of Rs.2.7 billion was a 21.2 per cent growth over last
year.
The Sector posted a revenue of Rs.11.5 billion
whilst operating profit and earnings stood at Rs.886.7 million and Rs.651.5
million respectively for the quarter. Performance was broad based with all
sectors growing competitively over last year. The growth in profitability was
primarily driven by the robust performance in Hospitals. However, profit
margins continued to be impacted due to challenges around forex liquidity.
Pharmaceuticals
Pharmaceutical
businesses delivered a stable revenue growth year to date. Price controls on
medicine coupled with scarcity in foreign exchange reserves have hampered medicine imports into the
country. This has led to medicine supply shortages within the industry whilst
adding to profitability pressure.
Additionally,
reduction in buy back volumes compared to assigned quantities under
the guaranteed buy back agreement with the Ministry of Health Sri
Lanka, continued to impact the overall performance. Excluding buyback
agreements, Pharmaceutical manufacturing arm, Morison reported a steady
cumulative growth of 35.2 per cent in revenue, driven by increased private
market sales.
Whilst we urge the government
to lay out a strategy for equitable allocation of buy back on local
manufacturers, we are looking at opportunities
to accelerate contract
manufacturing, exports and other alternative opportunities to de-risk Morison
from the volatility of the buyback agreements.
Due to the challenges in
the operating environment in Myanmar, we have entered into a sale and
purchase agreement with our joint venture partner to sell HHL’s stake
in Myanmar. As a result, we will be exiting the operations
in Myanmar, effectively from the fourth quarter onwards.
Hospitals
Hospitals witnessed an
average increase in admission volumes by 10.6 per cent over last year for the first
nine months.
The third quarter of
the year saw robust growth as the focus on non-COVID-19 patients was increased,
especially Non Communicable Diseases (NCDs), which pose a substantial risk to
the health of the people. Further, an outbreak of dengue was another
contributor to the increased admissions during the quarter.
Thalawathugoda and
Wattala recorded an overall occupancy of 66.7 per cent and 61.3 per cent
respectively for the quarter. Additionally, demand for diagnostics experienced
a surge in volumes in our laboratory network. Increased surgical admission volumes
further strengthened the EBITDA margin by registering a growth of 10 percentage
points against last year.
